Citigroup’s Revolution Medicines RVMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-30,000
Closed -$1.1M 6288
2025
Q2
$1.1M Hold
30,000
﹤0.01% 3123
2025
Q1
$1.06M Buy
+30,000
New +$1.22M ﹤0.01% 3220
2024
Q3
Sell
-62,600
Closed -$2.43M 5785
2024
Q2
$2.43M Buy
62,600
+41,600
+198% +$1.55M ﹤0.01% 2186
2024
Q1
$677K Sell
21,000
-68,900
-77% -$2.04M ﹤0.01% 3336
2023
Q4
$2.58M Buy
+89,900
New +$2.16M ﹤0.01% 2031

Other funds holding RVMD

Citigroup's RVMD Position: Q2 2026 in Review

Citigroup increased its Revolution Medicines (RVMD) stake by 175% in Q2 2026, buying an estimated $23M and bringing the position to 247,052 shares worth $46.3M. The position accounts for 0.02% of the portfolio, ranked #770.

Citigroup first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 692 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Citigroup held 247,052 shares of Revolution Medicines worth $46.3M as of Q2 2026.
  • Citigroup bought 157,310 Revolution Medicines shares in Q2 2026, an estimated $23M.
  • Revolution Medicines made up 0.02% of Citigroup's portfolio in Q2 2026, its #770 holding.
  • Citigroup first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 692 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.